Case Study: MirZyme Therapeutics achieves 93% preeclampsia risk detection with Imobisoft’s M-PREG platform

MirZyme Therapeutics achieves 93% diagnostic accuracy with Imobisoft

MirZyme Therapeutics faced the significant public health challenge of preeclampsia, a life-threatening pregnancy complication. Despite knowing the biological markers for prediction, they lacked a scalable way to translate that science into a usable clinical tool that could handle sensitive data and meet strict medical device regulations. The technology partner Imobisoft was engaged to develop the M-PREG digital diagnostic platform.

Imobisoft engineered a secure, cloud-based Software as a Medical Device (SaMD) solution that integrated MirZyme's proprietary algorithms. The resulting M-PREG platform achieved UKCA certification and enables clinicians to detect preeclampsia risk with 93% accuracy without the need for expensive hardware. This digital-first approach provides immense scalability and is projected to save healthcare systems billions by preventing premature births.

MirZyme Therapeutics